Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448

Jessica C Hassel¹, Lisa Zimmer^{2

3}, Thomas Sickmann⁴, Thomas K Eigentler⁵, Friedegund Meier⁶, Peter Mohr⁷, Tobias Pukrop^{8

9}, Alexander Roesch^{2

3}, Dirk Vordermark¹⁰, Christina Wendl¹¹, Ralf Gutzmer¹²

Affiliations

¹ Skin Cancer Center, Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany.
² Department of Dermatology, University Hospital Essen, 45147 Essen, Germany.
³ German Cancer Consortium (DKTK), Partner Site Essen, 69120 Heidelberg, Germany.
⁴ Bristol-Myers Squibb GmbH & Co. KGaA, 80636 Munich, Germany.
⁵ Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
⁶ Department of Dermatology, Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01062 Dresden, Germany.
⁷ Department of Dermatology, Elbe-Kliniken, 21614 Buxtehude, Germany.
⁸ Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, 93053 Regensburg, Germany.
⁹ Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany.
¹⁰ Department for Radiation Oncology, Martin-Luther University Halle-Wittenberg, 06108 Halle, Germany.
¹¹ Department of Radiology, University Hospital Regensburg, 93053 Regensburg, Germany.
¹² Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum, 32429 Minden, Germany.

Published Erratum

Jessica C Hassel et al. Cancers (Basel). 2025.

. 2025 Nov 21;17(23):3726.

doi: 10.3390/cancers17233726.

¹ Skin Cancer Center, Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany.
² Department of Dermatology, University Hospital Essen, 45147 Essen, Germany.
³ German Cancer Consortium (DKTK), Partner Site Essen, 69120 Heidelberg, Germany.
⁴ Bristol-Myers Squibb GmbH & Co. KGaA, 80636 Munich, Germany.
⁵ Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
⁶ Department of Dermatology, Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01062 Dresden, Germany.
⁷ Department of Dermatology, Elbe-Kliniken, 21614 Buxtehude, Germany.
⁸ Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, 93053 Regensburg, Germany.
⁹ Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany.
¹⁰ Department for Radiation Oncology, Martin-Luther University Halle-Wittenberg, 06108 Halle, Germany.
¹¹ Department of Radiology, University Hospital Regensburg, 93053 Regensburg, Germany.
¹² Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum, 32429 Minden, Germany.

Abstract

There was an error regarding the affiliations for Alexander Roesch [...].

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition.
Hassel JC, Zimmer L, Sickmann T, Eigentler TK, Meier F, Mohr P, Pukrop T, Roesch A, Vordermark D, Wendl C, Gutzmer R. Hassel JC, et al. Cancers (Basel). 2023 Jun 30;15(13):3448. doi: 10.3390/cancers15133448. Cancers (Basel). 2023. PMID: 37444558 Free PMC article. Review.

1. Hassel J.C., Zimmer L., Sickmann T., Eigentler T.K., Meier F., Mohr P., Pukrop T., Roesch A., Vordermark D., Wendl C., et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers. 2023;15:3448. doi: 10.3390/cancers15133448. - DOI - PMC - PubMed